Screenings for breast cancer and colon cancer dropped dramatically during the early months of the coronavirus pandemic, but use of the procedures returned to near-normal levels by the end of July 2020.
This study aimed to describe strategies CHCs use to integrate care with specialists and examine whether more strongly integrated CHCs have higher rates of screening for colorectal and cervical cancers and report better communication with specialists.
Patients prefer less invasive approaches such as fecal immunochemical test (FIT) for colorectal cancer screening, but the effectiveness of FIT depends on annual screenings for those with negative test results and colonoscopy if FIT tests are positive.
Each of the diagnostics for colorectal cancer has a different level of evidence supporting its ability to detect cancer and associated risks of serious adverse effects. More research is needed to clarify the evidence base.
This study systematically reviewed the evidence on the effectiveness, diagnostic accuracy, and harms of colonoscopy, flexible sigmoidoscopy, computed tomographic colonography, and stool tests for colorectal cancer screening.
Patients who visited their primary care provider one or more times were almost twice as likely to be screened for colorectal cancer and about 30 percent more likely receive a follow-up colonoscopy after a positive screening result.
Comparative modeling of colorectal cancer screening methods for previously unscreened adults found that the use of four strategies over different intervals between the ages of 50 and 75 years yielded a comparable balance of benefit and burden.
We validated 3 colorectal cancer (CRC) microsimulation models against outcomes from the United Kingdom Flexible Sigmoidoscopy Screening (UKFSS) Trial, a randomized controlled trial that examined the effectiveness of one-time flexible sigmoidoscopy screening to reduce CRC mortality.